State of New Jersey Common Pension Fund D Boosts Position in Glaukos Co. (NYSE:GKOS)

State of New Jersey Common Pension Fund D grew its holdings in shares of Glaukos Co. (NYSE:GKOS) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,883 shares of the medical instruments supplier’s stock after buying an additional 465 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $2,981,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Congress Asset Management Co. purchased a new stake in Glaukos in the fourth quarter worth $219,000. Rhumbline Advisers grew its stake in Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock worth $21,260,000 after purchasing an additional 403 shares during the period. Asset Planning Inc purchased a new stake in Glaukos in the fourth quarter worth $90,000. Legato Capital Management LLC grew its stake in Glaukos by 85.0% in the fourth quarter. Legato Capital Management LLC now owns 9,381 shares of the medical instruments supplier’s stock worth $1,407,000 after purchasing an additional 4,309 shares during the period. Finally, Louisiana State Employees Retirement System grew its stake in Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after purchasing an additional 100 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Down 1.6 %

GKOS opened at $157.97 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average price of $153.00 and a 200-day moving average price of $139.16. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The stock has a market capitalization of $8.71 billion, a price-to-earnings ratio of -52.31 and a beta of 1.04.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Equities research analysts forecast that Glaukos Co. will post -1.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group assumed coverage on Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price target on the stock. BTIG Research upped their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the company from $140.00 to $200.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $159.42.

Insider Activity

In related news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 over the last three months. Insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.